cdsco panel emergency use authorization covovax

CDSCO panel recommends emergency use authorisation for SII’s Covovax

Image Source : PTI

CDSCO panel recommends emergency use authorisation for SII’s Covovax

Highlights

  • An expert panel of CDSCO has recommended emergency use authorization for Covovax.
  • SII had submitted an application to DCGI in October for grant of market authorization for Covovax.
  • DCGI recently had sought to know the approval status of the application.

India’s central drug authority has recommended granting emergency use authorization to Serum Institute of India’s COVID-19 vaccine ‘Covovax’ with certain conditions, official sources said on Monday. An expert panel of the drug authority gave the recommendation. A CDSCO panel has also recommended restricted emergency use of anti-Covid pill Molnupiravir in India.

Prakash Kumar Singh, Director, Government, and Regulatory Affairs at Serum Institute of India (SII) had submitted an application to the Drugs Controller General of India (DCGI) in October for grant of market authorization for Covovax for restricted use in emergency situations.

“The Subject Expert Committee (SEC) on COVID-19 of the Central Drugs Standard Control Organisation (CDSCO) reviewed the emergency use authorization (EUA) application for the second time on Monday and after detailed deliberation recommended granting emergency use authorization to Covovax,” an official source said.

Noting the vaccine is the technology transfer of Novavax vaccine, the DCGI recently had sought to know the approval status of the application with regulatory authorities in the country of origin that is the USA.

The apex drug regulator had also asked the Serum Institute to provide details on Matrix component used in the vaccine. On November 27, the Subject Expert Committee on COVID-19 had evaluated and deliberated on SII’s application and sought additional data from the pharma company.

READ ALSO :  Bengal govt to give pocket money to stranded migrant workers

The Pune-based firm had submitted interim safety and immunogenicity data of phase 2/3 bridging clinical trial conducted in the country as well as interim clinical trial data of safety and efficacy from phase3 clinical trials conducted in the UK and the US along with its application.

The government had recently permitted the export of 2 crore doses of COVID-19 vaccine Covovax to Indonesia produced in India by SII, as the jab had not yet been approved for emergency use in the country, official sources had said.

The DCGI office had granted SII permission to manufacture and stock Covovax on May 17. Based on DCGI approval, till now, the Pune-based firm has manufactured and stockpiled the vaccine doses.

(With PTI Inputs)

Also Read: ‘Precautionary dose’ only applicable after 9 months of 2nd dose of COVID vaccine: Top doctor

Latest India News

Source link